Transfusion-related acute lung injury (TRALI) – review

Česká verzia

Authors: Z. Čermáková ¹; O. Šimetka ²; M. Kořístka ¹
Authors place of work: Krevní centrum FN, Ostrava, vedoucí pracoviště MUDr. Z. Čermáková, Ph. D. ¹; Porodnicko-gynekologická klinika FN, Ostrava, přednosta doc. MUDr. V. Unzeitig, CSc. ²
Published in the journal: Ceska Gynekol 2013; 78(2): 211-215

Summary

TRALI is a major cause of serious morbidity and mortality associated with a blood transfusion. It is clinically manifested by acute respiratory distress within 6 hours of completion of transfusion. Neutrophils have the key role in the pathogenesis. They are activated mostly with leukocyte antibodies (HLA and granulocyte) that are present mainly in plasma containing blood products. TRALI is a clinical diagnosis based on hy-poxemia and positive finding on lung X-ray examination. The treatment is only supportive and the mortality is about 5% to 10%. The major preventive measure is transfusing blood products from donors without leukocyte antibodies.

Keywords:
TRALI – blood transfusion – mortality – leukocyte antibodies

Zdroje

1. Bernard, GR., Artigas, A., Brigham, KL., et al. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care, 1994, 9, p. 72–81.

2. Bux, J. Antibody-mediated (immune) transfusion-related acute lung injury. Vox Sang, 2011, 100, p. 122–128.

3. Bux, J., Sachs, UJH. The pathogenesis of transfusion-related acute lung injury (TRALI). Brit J Hem, 2007, 136, p. 788–799.

4. Čermáková, Z., Kořístka, M., Blahutová, Š., et al. Transfusion-related acute lung injury: Report of two cases. Prag Med Rep, 2012, 113, 4, p. 294–298.

5. Davoren, A., Curtis, BR., Shulman, IA., et al. TRALI due to granulocyte-agglutinating human neutrophil antigen-3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion, 2003, 43, p. 641–645.

6. Flesland, O. A comparison of complication rates based on published haemovigilance data. Intensive Care Med, 2007, 33, suppl. 1, p. 17–21.

7. Goldman, M., Webert, KE., Arnold, DM., et al. Proceedings of a consensus conference: toward an understanding of TRALI. Trans Med Rev, 2005, 19, p. 2–31.

8. Chapman, CE., Stainsby, D., Jones, H., et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion, 2009, 49, p. 440–452.

9. Keller-Stanislawski, B., Reil, A., Gunay, S., Funk, MB. Frequency and severity of transfusion-related acute lung injury – German haemovigilance data (2006–2007). Vox Sang, 2010, 98, p. 70–77.

10. Khan, SY., Kelher, MR., Heal, JM., et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood, 2006, 108, p. 2455–2462.

11. Kleinman, S., Caulfield, T., Chan, P., et al. Toward an under-standing of transfusion-related acute lung injury: statement of a consensus panel. Transfusion, 2004, 44, p. 1774–1789.

12. Lögdberg, LE., Vikulina, T., Zimring, JC., et al. Animal model of transfusion-related acute lung injury. Transf Med Rev, 2009, 23, p. 13–24.

13. Mair, DC., Eastlund, T. The pathophysiology and preven-tion of transfusion-related acute lung injury (TRALI): a review. Immunohem, 2010, 26, p. 161–173.

14. Middelburg, RA., van Stein, D., Briet, E., van der Bom, JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion, 2008, 48, p. 2167–2176.

15. Moore, SB. Transfusion-related acute lung injury (TRALI): clinical presentation, treatment, and prognosis. Crit Care Med, 2006, 34, Suppl., p. 114–117.

16. Nishimura, M., Hashimoto, S., Takanashi, M., et al. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transf Med, 2007, 17, p. 129–134.

17. Popovsky, MA., Abel, MD., Moore, SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis, 1983, 128, p. 185–189.

18. Popovsky, MA., Moore, SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion, 1985, 25, p. 573–577.

19. Reil, A., Keller-Stanislawski, B., Günay, S., Bux, J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang, 2008, 95, p. 313–317

20. Rizk, A., Gorgon, KC., Kenney, L., Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion, 2001, 41, p. 264–268 .

21. Sachs, UJ. Recent insights into mechanism of transfusion-related acute lung injury. Curr Opin Hematol, 2011, 18, p. 436–442.

22. Sachs, UJ., Hattar, K., Weissmann, N., et al. Antibody-induced neutrofil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood, 2006, 107, p. 1217–1219.

23. Sachs, UJ., Wasel, W., Bayat, B., et al. Mechanism of transfusion-related acute lung injury induced by HLA class II antibodies. Blood, 2011, 117, p. 669–677.

24. Seeger, W., Schneider, U., Kreusler, B., et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood, 1990, 76, p. 1438–1444.

25. Serious Hazards of Transfusion (SHOT). Annual SHOT Report 2011. Available from http://www.shotuk.org/

26. Shaz, BH., Stowell, SR., Hillyer, CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood, 2011, 117, p. 1463–1471.

27. Silliman, CC., Ambruso, DR., Boshkov, LK. Transfusion-related acute lung injury. Blood, 2005, 105, p. 2266–2273.

28. Silliman, CC., Bjornsen, AJ., Wyman, TH., et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion, 2003, 43, p. 633–640.

29. Silliman, CC., Boshkov, LK., Mehdizadehkashi, Z., et al. Transfusion-related acute lung injury: epidemiology and prospective analysis of etiologic factors. Blood, 2003, 101, p. 454–462.

30. Silliman, CC., Curtis, BR., Kopko, PM., et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause PMN-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood, 2007, 109, p. 1752–1755.

31. Silliman, CC., Fung, YL., Ball, JB., Khan, SY. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev, 2009, 23, p. 245–255.

32. Silliman, CC., Kelher, M. The role of endothelial activation in the pathogenesis of transfusion-related acute lung injury. Transfusion, 2005, 45, Suppl., p. 109–116.

33. Silliman, CC., Voelkel, NF., Allard, JD., et al. Plasma and lipids from stored red cells cause acute lung injury in an animal model. J Clin Invest, 1998, 101, p. 1458–1467.

34. Sinnott, P., Bodger, S., Gupta, A., Brophy, M. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet, 2004, 31, p. 271–274.

35. Toy, P., Popovsky, MA., Abraham, E., et al. Transfusion-related acute lung injury: definition and review. Crit Care Med, 2005, 33, p. 721–726.

36. Triulzi, DJ. Transfusion-related acute lung injury: Current Concepts for Clinician. Anesth and Analg, 2009, 108, p. 770–776.

37. Wallis, JP., Lubenko, A., Wells, AW., Chapman, CE. Single hospital experience of TRALI. Transfusion, 2003, 43, p. 1053–1059.

38. Webert, KE., Blajchman, MA. Transfusion-related acute lung injury. Curr Opin Hematol, 2005, 12, p. 480–487.